- Aug 4, 2011 CORRECTING and REPLACING BioCryst Provides Corporate Update and Reports Second Quarter 2011 Financial Results
- Jul 26, 2011 BioCryst Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
- Jun 27, 2011 Kenneth Lee Appointed to BioCryst Pharmaceuticals' Board of Directors
- May 31, 2011 BioCryst to Present at Two Upcoming Investor Conferences
- May 26, 2011 BioCryst Presents New Analyses of BCX4208 Phase 2 Studies in Patients with Gout at the Annual European Congress of Rheumatology
- May 25, 2011 BioCryst Pharmaceuticals Announces Appointment of Thomas Staab as Its Next Chief Financial Officer
- May 4, 2011 BioCryst Provides Corporate Update and Reports First Quarter 2011 Financial Results
- May 3, 2011 BioCryst Pharmaceuticals Announces Changes to Its Board of Directors
- May 3, 2011 BioCryst to Present at Bank of America Merrill Lynch Healthcare Conference
- Apr 25, 2011 BioCryst Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
- Apr 22, 2011 BioCryst to Present New BCX4208 Gout Results at the Annual European Congress of Rheumatology
- Mar 9, 2011 BioCryst Announces Close of $30 Million Financing Transaction Related to Future RAPIACTA ( R ) Payments
- Feb 28, 2011 BioCryst to Present at Two Upcoming Investor Conferences
- Feb 24, 2011 BioCryst Awarded Additional $55.0 Million by the U.S. Department of Health & Human Services to Complete Peramivir Phase 3 Program
- Feb 24, 2011 Updated Fourth Quarter and Full Year 2010 Financial Results Revised as of February 24, 2011
- Feb 24, 2011 BioCryst Provides Corporate Update and Reports Fourth Quarter and Full Year 2010 Financial Results
- Feb 2, 2011 BioCryst Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on February 10, 2011
- Jan 13, 2011 BioCryst Announces Peramivir Phase 3 Safety & Virology Study Results and Provides a Clinical Program Update
- Jan 4, 2011 BioCryst to Present at J.P. Morgan Healthcare Conference
- Dec 22, 2010 BioCryst Initiates a Phase 2b Study of BCX4208 as Add-on Therapy in Gout Patients Not Responding to Allopurinol Alone
BCRX - NASDAQ